Printed From:

Access clinical trial publications for Toujeo®

Use the links below to read the study abstracts at

Toujeo® has been studied versus Lantus® (insulin glargine injection) 100 Units/ml in 4 pivotal clinical trials (the EDITION study program)a involving more than 3000 patients and in two euglycemic clamp studies to assess pharmacokinetics (PK) and pharmacodynamics (PD).1,3,4,6,8,11,12

aAll studies in the EDITION clinical program were 26-week, open-label, controlled, titrate-to-target, noninferiority studies in adults with diabetes not at A1C goal (range: 7% to 10% or 11 %), randomized to Toujeo® or Lantus® once daily. All patients were titrated to an FPG goal of 80-100 mg/dL (T2DM) or 80-130 mg/dL (T1DM).1,3,4,6,8

Your customers can pay only $10* for their Toujeo® prescriptions, regardless of formulary status*

*Eligibility restrictions apply.


  1. Toujeo Prescribing Information.
  2. Data on file. EDITION 3 CSR. Sanofi.
  3. Bolli GB, Riddle MC, Bergenstal RM, et al; the EDITION 3 Study Investigators. Diabetes Obes Metab. 2015;17(4):386-394.
  4. Data on file. EDITION 2 CSR. Sanofi.
  5. Yki-Järvinen H, Bergensta lR, Ziemen M, et al; the EDITION 2 Study Investigators. Diabetes Care. 2014;37(12):3235-3243.
  6. Riddle MC, Bolli GB, Ziemen M, et al; the EDITION Study Investigators. Diabetes Care. 2014;37(10):2755-2762.
  7. Data on file. EDITION 1 CSR. Sanofi.
  8. Home PD, Bergenstal RM, Bolli GB, et al; the EDITION 4 Study Investigators. Diabetes Care. 2014;38(12):2217-2225.
  9. Data on file. EDITION 4 CSR. Sanofi.
  10. Becker RHA, Dahmen R, Bergmann, Lehmann A, Jax T, Heise T. Diabetes Care. 2015;38(4):637-643.
  11. Becker RHA, Nowotny I, Teichert L, Bergmann K, Kapitza C. Diabetes Obes Metab. 2015;17(3):261-267.